Infinitus Systems

Infinitus Systems is a technology company.

Active

Updated: Feb 17, 2026 ·

Recent News & Mentions

Oct 1, 2024FundingInfinitus Systems - Series C Nov 1, 2021FundingInfinitus Systems - Series B Feb 1, 2021FundingInfinitus Systems - Series A

Financial History

Infinitus Systems has raised $103.0M across 3 funding rounds. Most recently, it raised $52.0M Series C in October 2024.

Total Raised

$103.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Oct 1, 2024	$52.0M Series C	Andreessen Horowitz, ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, GV, Pfizer Venture Investments, Quiet Capital, RA Capital, SR One, Bill Gates, Diego Oppenheimer, Gokul Rajaram, Yan-David Erlich
Nov 1, 2021	$30.0M Series B	ARCH Venture Partners, Atlas Venture, GV, Pfizer Venture Investments, RA Capital, SR One, Bill Gates
Feb 1, 2021	$21.0M Series A	Arthur Ventures, First Round Capital, Javelin Venture Partners, Uncork Capital, Western Technology Investment

Financial History

Infinitus Systems has raised $103.0M across 3 funding rounds.

Total Raised

$103.0M

Valuation

N/A

Deep Dive

Infinitus Systems is a healthcare-focused AI company that builds voice AI agents to automate routine phone calls between providers, payors, pharmacies and patients, reducing manual work and hold times for administrative healthcare tasks.[5][4]

High-Level Overview

Infinitus Systems is a Voice AI platform provider that automates clinical and administrative healthcare phone calls (benefits verification, prior authorization, pharmacy calls, etc.) using autonomous AI agents such as its digital assistant Eva to offload repetitive call volume for health systems, specialty pharmacies, payors and biopharma programs[5][1].[2] The product is positioned to save organizations time and money (Infinitus reports typical ROIs near 50% and measurable increases in data accuracy) while improving patient and staff experience by reducing hold times and manual workflows[5][2].[5]

Origin Story

Infinitus was founded in 2019 and is headquartered in San Francisco, with co‑founders including Ankit Jain (CEO) and Shyam Rajagopalan (CTO); Jain previously led engineering at Google and Rajagopalan worked in security at Snap, per early company profiles and coverage when the company emerged from stealth with initial funding in 2021[1].[1] The idea grew from addressing persistent, high‑volume phone-based workflows in U.S. healthcare that still rely on manual calls between payors, providers and pharmacies; early traction included rapid provider adoption (tens of thousands of providers by 2021) and venture backing from notable firms such as GV, Coatue, and Kleiner Perkins[1].[1]

Core Differentiators

Voice-first AI agents tailored for healthcare: Infinitus builds AI specifically to conduct whole phone-call interactions in regulated healthcare contexts rather than generic chatbots, emphasizing domain accuracy and guardrails for sensitive workflows[2][4].
Deep healthcare integrations and partnerships: The company has built API and EHR integrations (including a SMART on FHIR application) and partnerships with enterprise platforms like Salesforce and Google Cloud to launch agents within existing workflows[2][3].
Proven scale and outcomes: Infinitus reports over 100 million minutes automated and millions of calls completed supporting 125,000+ providers, plus claimed operational ROI and improved data accuracy for customers[2][5].
Enterprise readiness and product suite: Recent launches such as FastTrack (an AI copilot to bypass IVRs and assist staff) signal focus on enterprise features that augment staff as well as fully autonomous agents[2].
Credibility and recognition: Fast Company named Infinitus to its World’s Most Innovative Companies list in 2025, reflecting external validation of its approach to healthcare voice automation[2].

Role in the Broader Tech Landscape

Trend alignment: Infinitus rides the broader trend of generative AI and autonomous agents being applied to domain-specific, high-friction workflows—particularly where voice/telephony remains central to operations (healthcare benefits, prior auth, pharmacy coordination)[2][5].
Timing and market forces: Chronic staffing shortages and rising administrative burden in U.S. healthcare create demand for automation that preserves human clinicians for higher‑value work, increasing receptivity to agentic automation that can integrate into EHRs and call workflows[4][5].
Network and ecosystem influence: By partnering with major cloud and enterprise software companies and integrating into EHR/CRM flows, Infinitus amplifies adoption across providers, payors and pharma, potentially shifting how routine communication is routed and automated in health systems[3][2].
Risks and constraints: Adoption depends on accuracy, regulatory/compliance safeguards, interoperability (FHIR/EHR access), and trust from clinicians and patients—areas Infinitus explicitly emphasizes but that remain industry-wide challenges[4][2].

Quick Take & Future Outlook

Infinitus is positioned to expand as healthcare organizations prioritize reducing administrative burden and as voice AI models improve; near-term growth vectors include deeper EHR and CRM embedding, scaling enterprise features (like FastTrack), and expanding into adjacent administrative workflows across payors and pharma programs[2][5]. Continued success will depend on maintaining high accuracy and compliance, proving ROI at scale, and broadening partnerships that place agents directly in clinician and reimbursement workflows[4][3]. If Infinitus sustains its technical and regulatory rigor while scaling integrations, it could become a standard platform for automating phone‑based healthcare operations—effectively making a previously manual layer of healthcare communication far more efficient[5][2].

Sources

Frequently Asked Questions

How much funding has Infinitus Systems raised?

Infinitus Systems has raised $103.0M in total across 3 funding rounds.

Who are Infinitus Systems's investors?

Infinitus Systems's investors include Andreessen Horowitz, ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, GV, Pfizer Venture Investments, Quiet Capital, RA Capital, SR One, Bill Gates, Diego Oppenheimer, Gokul Rajaram.